- Home
- PSTV vs CVKD Comparison
PSTV vs CVKD Comparison
Compare PSTV & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSTV | CVKD |
|---|---|---|
| Founded | 1996 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.1M | 20.7M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | PSTV | CVKD |
|---|---|---|
| Price | $0.57 | $7.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $7.25 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 6.3M | 73.3K |
| Earning Date | 10-30-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,258,000.00 | N/A |
| Revenue This Year | $28.21 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.16 | $7.17 |
| 52 Week High | $2.31 | $22.90 |
Technical Indicators
Market Signals| Indicator | PSTV | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 46.39 | 34.09 |
| Support Level | $0.61 | $7.43 |
| Resistance Level | $0.65 | $12.50 |
| Average True Range (ATR) | 0.06 | 1.10 |
| MACD | -0.01 | -0.23 |
| Stochastic Oscillator | 18.79 | 7.86 |
Price Performance
Historical ComparisonAbout PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.